Campylobacter curvus

(aka Wolinella curva)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Campylobacter curvus, (aka Wolinella curva), is a Gram-negative, non-spore-forming, microaerophilic, motile, helical-shaped bacterium. It has been detected in at least 5 gut microbiome compilation studies or metastudies. The DNA G+C content is 43–47%. Campylobacter curvus is probably a rare gut coloniser. (Vandamme1991; VanDamme2005Bergey; Liu2018a; Tanner1984)



  • This organism has been recovered from clinical sources and human faeces. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. A possible gut commensal.
    • GENERAL CHARACTERISTICS (Vandamme1991); (VanDamme2005Bergey); (Tanner1984);
    Character Response
  • ±
  • Strain-dependent hydrolysis or digestion:
  • hippurate;
  • 🧂
  • Salt tolerance:
  • strain-variable at 2.0(d)%;
  • 🌡
  • Temperature tolerance:
  • doesn't grow at 25℃; strain-variable at 42(d);
  • ⥅
  • Substrates assimilated or utilised:
  • glycine; formate; fumarate;
  • ±
  • Strain-dependent substrate utilisation:
  • hippurate;
  • Active enzymes:
  • alkaline phosphatase; oxidase;
    • SPECIAL FEATURES (VanDamme2005Bergey); (Tanner1984);
    Character Response
  • ✓
  • Metabolites produced:
  • formate; acetate (major); succinate; H₂S; CO₂; H₂;
  • ✗
  • Metabolites not produced:
  • indole;
  • ✗
  • VP test:
  • not active
  • ✓
  • Nitrate:
  • reduced
  • ✓
  • Nitrite:
  • reduced
    • RESPONSE TO ANTIBIOTICS (VanDamme2005Bergey); (Tanner1984);
    Class Active Resistant
  • Penicillins:
  • carbenicillin;
  • Cephalosporins:
  • cephalothin;
  • cefoperazone;
  • Macrolides:
  • erythromycin;
  • Tetracyclines:
  • tetracycline;
  • Quinolines:
  • nalidixic-acid;
  • Aminoglycosides:
  • gentamicin;
  • kanamycin;
  • Polypep/ketides:
  • bacitracin; rifampicin;
  • Heterocycles:
  • chloramphenicol; metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin; colistin;
  • polymyxin B;
  • NOTES

    Media containing 1% glycine supports growth.

  • Bacterium Selenite reduction H2S/TSI Nitrate reduction Oxidase Catalase Indoxyl acetate hydrolysis
    Campylobacter coli + d + + + +
    Campylobacter upsaliensis + neg + + neg +
    Campylobacter rectus + neg + + d +
    Campylobacter showae + d + d + neg
    Campylobacter concisus d neg d d neg neg
    Campylobacter curvus neg d + + neg d
    Campylobacter gracilis neg neg d neg d d
    Campylobacter hominis neg neg neg + neg neg

  • Hansen, R., Berry, S. H., Mukhopadhya, I., Thomson, J. M., Saunders, K. A., Nicholl, C. E., Bisset, W. M., Loganathan, S., Mahdi, G., Kastner-Cole, D., Barclay, A. R., Bishop, J., Flynn, D. M., McGrogan, P., Russell, R. K., El-Omar, E. M., & Hold, G. L. (2013). The microaerophilic microbiota of de-novo paediatric inflammatory bowel disease: the BISCUIT study. PloS One, 8(3), e58825.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Proteobacteria Class:  Epsilonproteobacteria Order:  Campylobacterales Family:  Campylobacteraceae Genus:  Campylobacter Alt. name:  Wolinella curva Gram stain:  neg O2 Relation.:  microaerophilic Spore:  No spore Motility:  Swimming Morphology:  Helical
    Health:  Unknown
    Source:  clinical sources and human faeces
    DNA G+C(%):  43–47
    Lower T(℃):  25(neg)
    High T(℃):  42(d)
    NaCl 0.5-2%:  2.0(d)
    		Aesculin:  neg Urea:  neg Gelatin:  neg Starch:  neg Casein:  neg DNA:  neg Tyrosine:  neg Hippurate:  d(neg)
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Glucose:  neg Mannose:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Gly:  + Hippurate:  d Formate:  + Fumarate:  +
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  + Catalase:  neg Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg α-Mannosidase:  neg ArgDH:  neg ArgDC:  neg γ-Glu transf.:  neg GluDC:  neg LysDC:  neg OrnDC:  neg AlanineAA:  neg GluGluAA:  neg GlyAA:  neg LeuAA:  neg LeuGlyAA:  neg PyrrolidAA:  neg AlkalineP:  + AcidP:  neg Esterase(C4):  neg EstLip(C8):  neg Lecithinase:  neg Lipase:  neg Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Formate:  + Acetate:  Major(+) Succinate:  + H2S:  + CO2:  + H2:  + Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    carbenicil:  S(32)
    penicillin:  Var(MIC50): 32), MIC90: Var(32
    penicillin_G:  Var(MIC50): 0.5, MIC90: -, RNG: (0.25->64)
    cefoperazone:  R(64)
    cephalothin:  S(32)
    gentamicin:  S(2)
    kanamycin:  R(8)
    neomycin:  Var(MIC50): 4-8), MIC90: Var(4-8
    streptomycin:  Var(MIC50): 2), MIC90: Var(2
    erythromycin:  S(2)
    nalidixic-acid:  R(MIC50): 32), MIC90: R(32, R(64-128)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    minocycline:  Var(MIC50): 2-4), MIC90: Var(2-4
    tetracycline:  S(1)
    vancomycin:  R(128)
    bacitracin:  R(128)
    rifampicin:  R(128)
    chloramphenicol:  SensRNG: (2-4)
    metronidazole:  S(4)
    clindamycin:  SensRNG: (0.5-1)
    colistin:  S(4)
    polymyxin_B:  R(8)

    References

    SPECIFIC REFERENCES FOR CAMPYLOBACTER CURVUS
  • Vandamme1991 - Revision of Campylobacter, Helicobacter, and Wolinella Taxonomy: Emendation of Generic Descriptions and Proposal of Arcobacter gen. nov.
  • VanDamme2005Bergey - Bergey's manual of systematic bacteriology. Vol. 2, The Alpha-, Beta-, Delta-, and Epsilonproteobacteria Part C. Family Campylobacteraceae, Genus I. Campylobacter
  • Liu2018a - The Clinical Importance of Campylobacter concisus and Other Human Hosted Campylobacter Species.
  • Tanner1984 - Wolinella curva sp. nov.: Vibrio succinogenes of Human Origin.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR CAMPYLOBACTER CURVUS
  • Almeida2019 - A new genomic blueprint of the human gut microbiota.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • GENERAL REFERENCES FOR CAMPYLOBACTER CURVUS
  • VanDamme2005Bergey - Bergey's manual of systematic bacteriology. Vol. 2, The Alpha-, Beta-, Delta-, and Epsilonproteobacteria Part C. Family Campylobacteraceae, Genus I. Campylobacter
  • VanDamme2005aBergey - Bergey's manual of systematic bacteriology. Vol. 2, The Alpha-, Beta-, Delta-, and Epsilonproteobacteria Part C. Family Campylobacteraceae, Genus II. Arcobacter
    • Added: April 08, 2021